Self-reported diagnoses of inflammatory arthritis are not accurate. The primary study aim was to ascertain self-reported diagnoses of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in the Norwegian population-based Nord-Trøndelag Health Study (HUNT) using hospital case files. The secondary aim was to provide updated estimates of prevalences and incidences of RA and AS.
INTRODUCTION
Population-based health surveys can provide important information regarding the prevalence and incidence of inflammatory arthritis and may also include quality-of-life data and life-style factors.
However, self-report is prone to bias. Although clinic-or hospital-based data may enable collection of more in-depth information on disease characteristics, lower prevalences may indicate selection bias (1, 2) . Comparisons with the general population are usually not possible due to the paucity of communitylevel data. Registry-based studies are useful if the quality of data is sufficiently high, e.g. by combining various data sources such as billing and hospitalization data, prescription registries etc. (1, 3) . Registry-based data usually do not permit further analysis on disease characteristics. Thus, these different approaches each have different strengths and weaknesses.
The main aim of the present study was to investigate the quality of self-reported data on rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in the population-based Nord-Trøndelag Health Study (HUNT) in Norway. All inhabitants > 20 years of age in the county of Nord-Trøndelag were invited.
The county is fairly representative for Norway as a whole, with a stable and ethnically homogenous population (4) . We have previously published results showing higher incidences of RA and AS in HUNT than expected from the literature (3, (5) (6) (7) (8) (9) , potentially indicating a high number of false-positive self-reports. We have therefore now ascertained the diagnoses using hospital case files, also noting any alternative diagnosis explaining the patient's complaints in cases that were not RA or AS. The secondary aim of the study was to provide updated estimates of the prevalences and incidences of RA and AS, because previous Norwegian estimates are old and scarce (7, 8, 10, 11) .
METHODS
Data were from participants in the second (1995) (1996) (1997) ) and third (2006) (2007) (2008) HUNT surveys. The study has been described previously (4) . Participants filled in questionnaires and met for a clinical examination. We used questionnaire data focusing on self-reported RA and/or AS. The file from HUNT contained 65,214 participants from HUNT2 (participation rate 69.5%) and 50,797 participants from HUNT3 (participation rate 54.1%); 33,383 participated in both these surveys. After exclusion of those with missing answers to the questions "Has a doctor ever said that you have/have had any of these diseases: rheumatoid arthritis; ankylosing spondylitis?" (using the Norwegian denomination Bekhterev's disease), 70,805 unique participants were included ( Figure 1 ).
For participants with self-reported RA and/or AS, the diagnosis was ascertained in hospital case files from the three hospitals in Central Norway (Levanger Hospital, Namsos Hospital, and St Olavs Hospital), using the European League Against Rheumatism (EULAR) 2010 criteria for RA and the Modified New York criteria for AS (12, 13) . The files were carefully evaluated by an experienced immunologist (VV) according to a pre-defined protocol, and the conclusions were compared to those of the treating rheumatologists (see Supplementary information). All cases with inconsistencies or unclear information were reviewed by an experienced rheumatologist (MH) for a final decision. The files from 25 randomly selected individuals previously reviewed by VV were examined by MH without knowledge of the previous conclusion. There was complete agreement between the two examiners, i.e. a kappa interrater agreement of 1.
In the Norwegian health care system, a diagnosis of RA and AS is given by a rheumatologist and only a rheumatologist may start disease-modifying anti-rheumatic drug (DMARD) treatment.
There are no private rheumatologists in Central Norway, so all patients were followed up at the outpatient and/or in-patient clinics of the Department of Rheumatology at one of the mentioned hospitals.
The case files contained notes from in-patient and out-patient visits. The role of the family physician in the care of these patients was minor. For long-standing RA cases with incomplete information on the EULAR criteria, a rheumatologist's diagnosis according to ACR criteria was accepted, [14] . Selfreported cases with missing files or unclear information were excluded from the validated cases. Year of diagnosis was recorded, as well as presence of IgM rheumatoid factor and anti-citrullinated protein antibodies (ACPA) in the RA cases, permitting classification as seropositive disease (one or both autoantibodies positive) or seronegative disease (no autoantibodies present). We also noted whether AS patients were HLA-B27 positive or negative.
To estimate the number of false-negative cases, one random age-and gender-matched participant was drawn from the same wave of HUNT for each person of a random sub-selection of participants with a self-reported diagnosis of RA or AS (n=3,434). For these controls, the diagnosis registries of the For all calculations involving total participant numbers, the numbers from Figure 1 were used, i.e. including participants with missing or incomplete case files.
RESULTS
In total, 544 cases of RA and 187 cases of AS were identified from hospital case records. Of these, 538 RA cases (98.9%) had a self-report of RA and/or AS (Details in Table 1 ). 6 cases (1.1%) were found via the search in the matched controls. These persons had only participated in HUNT2 and were given their diagnosis later; thus, they were not truly false-negative cases. The false-positive rate of a selfreport of RA was 82%, the false-negative rate was 0%, and the positive and negative likelihood ratios were 1.5 and 0.03, respectively. For AS 186 cases (99.5%) had a self-report, and 1 case (0.5%) was found among the matched controls (Table 1 ). This single AS case was truly false-negative with the diagnosis given between participation in HUNT2 and HUNT3. The false-positive rate of a self-report of AS was 86%, the false-negative rate was <0.1%, and the positive and negative likelihood ratios were 3.5 and 0.007, respectively.
Of the total 70,805 HUNT participants, 4.2% self-reported RA or a combination of RA and AS and 1.9% self-reported AS or a combination of RA and AS. Of the 2,703 participants only self-reporting RA, 516 had a correct diagnosis confirmed in the hospital records, giving a true positive rate of 19.1% (Table 2, Supplementary table 1) . The diagnosis was correct in 168 of the 1,065 participants only selfreporting AS, giving a true positive rate of 15.8%. The percentages of correct diagnosis were even lower for participants who self-reported both diagnoses either at the same HUNT survey or in other combinations (Table 2 ). Overall, for those self-reporting a diagnosis of RA, AS or both, the diagnosis could not be verified in 82.1% including 22.8% with too little information or no available patient file.
The most common diagnoses in false-positive self-reported RA were osteoarthritis, psoriasis arthritis and miscellaneous other arthritis (29.1%) ( Table 2, Supplementary table 1) . The most common diagnoses in false-positive self-reported AS were non-rheumatologic disease (22.7%) and degenerative changes (15.3%). False-positive RA was equally frequent in both genders (p=0.52), whereas falsepositive AS was more frequent in women (56% vs. 44% men, p<0.0005). False-positive cases for RA where slightly younger than the true-positives (HUNT2: 55 (17) (12) years, p<0.01).
Prevalence and incidence data for RA and AS based on confirmed diagnoses are given in Table 3 Further characteristics of the validated RA and AS cases are given in Table 4 . Approximately 3/4 of the RA cases were seropositive with no difference in frequency between men and women (p=0.31).
There were more HLA-B27 negative AS cases in women (18.5% vs. 7.5%, p=0.03). Age at diagnosis was not significantly different between women and men (RA: p=0.19; AS: p=0.53). The frequency of HLA-B27 positive blood donors (n=745) was 13.13(10.9-15.9)%.
DISCUSSION
In the present large population-based study covering approximately 11 years, self-reported RA could be verified in 19.1% and self-reported AS could be verified in 15.8%. However, the false-negative rate was very low, indicating that few cases were lost based on self-report. The overall prevalence per 100,000 was 768(705-835) for RA and 264(228-305) for AS. The yearly incidence per 1000 was 0.48(0.41-0.56) for RA and 0.19(0.15-0.24) for AS. The most common diagnoses in false-positive self-reported RA were other forms of arthritis, whereas in AS they were non-rheumatologic disease and degenerative changes.
Validity of self-reported diagnoses
Our data confirm previous results showing that the specificity of self-reported RA is high (15) , but that self-report of arthritis gives many false-positives. Our data on RA are comparable with old studies from Oslo, Norway, and Baltimore, USA, indicating 21-31% correct self-reports (16, 17) , and with data from the Women's Health Initiative showing 14.7% correct diagnoses (18) . Only 7% of selfreported RA cases were correct in the Nurses' Health Study and 5% in the Iowa Women's Health Study (19, 20) . A Spanish study showed that self-reported health survey data indicated twice as many cases of arthritis and rheumatism than shown by electronic health records, i.e. 22.7% vs. 11.3% (21) .
On the other hand, a recent meta-study concluded that self-reported RA had acceptable accuracy with a sensitivity of 88% (59-97%) and a specificity of 93% (66-99%) (22) . Sensitivity is defined as the probability that a patient self-reports an arthritis diagnosis if he or she truly has arthritis. For population-based studies, high false-positive rates are of greater concern than sensitivity as one would include a large number of patients without disease in the arthritis group if no further diagnostic ascertainment is included, thereby "diluting" the differences between cases and controls and overestimating the need of health care.
We are not aware of comparable studies regarding the validity of self-reported AS. In the National Several suggestions have been made to reduce the false-positive rates when identifying arthritis patients in population-based studies. Linkage to central health databases is one such approach, but depends heavily on the quality of the collected data. Diagnostic codes may be missing if the main diagnosis was something else, or a non-rheumatologist may report an inaccurate diagnosis based on the patient's self-report or previous case notes.
Inclusion of self-reported medication data or data from prescription registries increases accuracy (25) .
However, some drugs may be used for other conditions, e.g. DMARD for psoriasis arthritis as well as RA, or biologic DMARDs for colitis-associated arthritis as well as AS. Patients with mild symptoms may not be using medication or only be using non-specific drugs such as non-steroid antiinflammatory drugs.
Measurement of ACPA improves diagnostic accuracy of RA, but leads to omission of seronegative cases (26) . Similarly, restricting self-reported AS only to known HLA-B27 positive cases will lead to case loss.
We are currently testing a questionnaire aiming to identify the most likely truly positive RA and AS cases in population-based studies. The final, abbreviated and validated version of this questionnaire will be included in the forthcoming HUNT4 study, to investigate whether a more specific questionnaire may help reduce the number of false-positives. However, it is unlikely that sufficiently accurate case identification is possible based on questionnaires alone, even when including questions pertaining to medication and visits at rheumatology clinics; thus validation from a rheumatologist's case files or a highly accurate diagnostic registry is probably necessary. A good questionnaire may reduce the number of cases needing a further check. Some form of diagnostic validation should probably be included in the protocols for other population-based studies on inflammatory arthritis prior to their implementation.
Prevalence and incidence of RA
Our prevalence data for RA were higher than previous data from Oslo, Norway (Table 5 ) (19) , but the prevalence in Oslo was lower than expected and excluded persons older than 79 years. Our data from HUNT 3 were comparable with recent Swedish data for the older women and men (27) , whereas the HUNT2 prevalences were lower. The number of cases in younger participants in our study was too low for a meaningful comparison. Total prevalences from Minnesota, USA from 1995 are in agreement with HUNT2, and data from 2005 are in agreement with HUNT3 (28) . Minnesota has many inhabitants of Scandinavian decent. Our data also confirm previous findings of higher prevalences of RA in Northern than Southern Europe, e.g. when comparing to recent Italian data (29) .
Our findings suggest an increased prevalence in RA from HUNT2 to HUNT3. This may be related to the higher number of missing data for case ascertainment for HUNT2 participants, especially in older persons who would be more likely to have RA, thereby biasing the estimates downwards. Our HUNT3 data are therefore probably more accurate. Some of the differences in prevalences from other studies may be related to participation rates among different age and gender groups in HUNT. Both in HUNT2 and HUNT3, participation was relatively lower in the younger age groups; more so for men than for women (4) . Furthermore, anonymous data from general practitioners indicated less longlasting musculoskeletal pain in non-participants than participants in HUNT3 (36). These factors would tend to bias our prevalence estimates for RA upwards.
Our incidence data for RA are also in good agreement with data from Sweden, Norfolk/UK, and Minnesota (3, 28, 30) , especially for women (Table 5) . Some of the differences may be explained by adjustments to reference populations, as well as by the participation rates in HUNT. Previous data from Oslo showed lower incidences, but that registry excluded patients older than 79 years (7).
Prevalence and incidence of AS
Prevalences of AS are known to vary greatly between populations, largely due to different carrier frequencies of HLA-B27 (2) . Previous Norwegian studies were from different parts of northern Norway, with much higher prevalences in the city of Tromsø, which has an ethnically mixed population (8, 11) ( Table 5 ). The prevalence for the entire region was close to that in HUNT, with an increase from the 1970s to the 1990s (8) . Swedish prevalences were highest in western and northern regions, i.e. areas closer to the catchment area for HUNT (31) . Our data from HUNT3 are in good agreement with the Swedish data in men and women over 40 years, but higher in individuals below 40 years. The explanations may be similar to those for RA. Prevalences from southern Sweden were lower (32) .
Even though the prevalences of AS in HUNT2 may be too low due to missing data and HUNT participation frequencies, it is conceivable that there has been a true increase from HUNT2 to HUNT3, in accordance with findings from northern Norway and Ontario, Canada (8, 33) . Better imaging tools, higher diagnostic awareness, and recognition that HLA-B27 negativity and female gender do not rule out the diagnosis are contributing factors. Our data suggest that the proportion of HLA-B27 negative cases may be higher in women than in men, an observation that merits further study as it may be related to misdiagnosis. It is also noteworthy that the age at diagnosis in HUNT was comparable in women and men (p=0.53), in contrast to previous findings (33) .
Few previous studies complicate the comparison of AS incidences. The incidence of AS in HUNT was higher than in a previous study from northern Norway (Table 5) , where the carrier frequency of HLA-B27 reported in an old study of 176 blood donors (15.9%) was not significantly different from our study (13.1%, p=0.32) (8,37). The incidence was comparable to a population-based study from Ontario where the prevalence also was similar (33) . Czech and Finnish studies showed lower incidences (34, 35).
Limitations
The main limitation was the extent of non-participation which may have biased the results. Missing information for case validation, and patients with long-standing or mild disease who may only have been followed up in primary care could have reduced the number of identified cases. Some patients may have moved from Nord-Trøndelag, resulting in case files not being updated. However, mobility of the catchment population for HUNT has been relatively low. The EULAR 2010 and modified New York criteria for RA and AS, respectively, were not developed for ascertainment of self-reported diagnoses. Blood donors are a selected healthy group and only those volunteering to become bone marrow donors were HLA typed, which may have biased the estimated frequency of HLA-B27 carriers in Central Norway.
Conclusions
Our study confirmed that self-reported diagnoses of RA in population-based studies are not accurate, and that self-reported AS is no more accurate. Thus, validation from a rheumatologist's case files or a highly accurate diagnostic registry is necessary. The prevalences and incidences of RA in HUNT were comparable to those from similar populations. There may have been a true increase in the prevalence of AS from HUNT2 to HUNT3, especially in women. The higher frequency of HLA-B27 negative cases in women merits further investigation. The incidence of AS was higher than previously reported in a mixed population from Norway. The information was entered into a spreadsheet. The protocol had an appendix briefly stating the criteria for the relevant rheumatological diagnoses (RA, AS, nrAxSpA, PsA, IBD-associated arthritis, reactive arthritis, osteoarthritis, fibromyalgia, and gout). Figure 1 
